Lipson Discusses Treatment Selection, Toxicity, and Duration of IO in Melanoma
Source: Targeted Oncology, February 2025
During a Case-Based Roundtable® event, Evan J. Lipson, MD, moderated a discussion on the tolerability of immunotherapy in metastatic melanoma and when to stop therapy.
EVENT REGION Maryland and Virginia
PARTICIPANT LIST Daya Sharma, MD | Nelson Kalil, MD | Raj Manchandani, MD | Arun Bhandari, MD | Sekwon Jang, MD | Jackson Gao, MD | David Weng, MD | M. Kelly Hagan, MD | Bill Gai, MD | Ligeng Tian, MD | Jose Mendoza, MD | Kumar Abhishek, MD
CASE SUMMARY
A man aged 78 years with a history of stage III melanoma underwent surgical resection 12 years ago. On routine follow-up, the patient presented with moderate asthenia that limited his daily activities. His ECOG performance status was 1, and his physical examination was unremarkable. Notable laboratory findings included a lactate dehydrogenase level of 380 U/L (reference range, 110-240 U/L). A full-body CT scan revealed pulmonary and hepatic nodules, but MRI showed no evidence of brain metastases. He underwent a core needle biopsy of the largest hepatic lesion in segment IVb without any complications. Pathology findings revealed metastatic melanoma, and mutation testing results showed it was negative for BRAF mutations.